Homology Medicines Presents Data from PKU Gene Therapy Program Demonstrating Long-Term Durability of Treatment in IND-Enabling Studies

Presentations Also Demonstrate Phenotypic Correction of PKU Model with Homology’s Nuclease-Free Gene Editing Approach and Ability of Platform to Target Ophthalmic Disorders BEDFORD, Mass., May 18, 2018 /PRNewswire/ — Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the presentation